• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

December 21, 2020
Company Drug/Device Medical Condition Status
COVID-19 Trials and Actions
AbbVie ABBV-47D11 adults hospitalized with COVID-19 initiation of phase 1 trial
Codagenix and the Serum Institute of India COVI-VAC single-dose intranasal, live attenuated vaccine against SARS-CoV-2 initiation of phase 1 trial
FSD Pharma FSD201 (ultramicronized palmitoylethanolamide) hospitalized patients with COVID-19 first patient dosed in phase 2a trial
ARCA Bio rNAPc2 (AB201) patients hospitalized with COVID-19 first patients dosed in phase 2b trial
Abpro ABP 300 treatment of COVID-19 initiation of phase 2/3 trial
CureVac CVnCoV mRNA COVID-19 vaccine first patient enrolled in phase 2b/3 trial
Pfizer

BioNTech
COVID-19 vaccine COVID-19 Emergency Use Authorization (EUA) granted by the FDA
Abbot BinaxNOW COVID-19 Ag Card rapid test detection of COVID-19 infection EUA granted by the FDA
Applied BioCode BioCode SARS CoV-2 molecular diagnostic assay with pooled patient samples pooled COVID-19 testing EUA granted by the FDA
Ellume Ellume rapid, at-home COVID-19 antigen test home use for the detection of active COVID-19 in individuals with or without symptoms, and in adults and children aged 2 years and above EUA granted by the FDA
Other Trials and Actions
CNS Pharma Berubicin glioblastoma multiforme IND approved by the FDA
Entera Bio EB613 osteoporosis IND approved by the FDA
Graphite Bio GPH101 severe sickle cell disease IND approved by the FDA
V2ACT Therapeutics V2ACT newly diagnosed surgically resectable pancreatic cancer IND approved by the FDA
Arecor AT278, ultra-concentrated rapid acting insulin diabetes first patient dosed in phase 1 trial
Kineta KCP506 chronic neuropathic pain first patient dosed in phase 1 trial
Liminal BioSciences fezagepras idiopathic pulmonary fibrosis first patient dosed in phase 1 trial
Plus Therapeutics Rhenium NanoLiposome recurrent glioblastoma completion of the sixth dosing cohort in phase 1 trial
Protagonist Therapeutics PN-235 (JNJ-77242113) inflammation first patient dosed in phase 1 trial
Synlogic SYNB1891 intratumoral treatment of solid tumors and lymphoma initiation of combination therapy stage of ongoing phase 1 trial
Cerecor CERC-007 relapsed or refractory multiple myeloma first patient dosed in phase 1b trial
STALICLA STP1 autism spectrum disorder first patient enrolled in phase 1b trial
TFF Pharmaceuticals Voriconazole Inhalation Powder aspergillosis infections in patients with asthma first patient dosed in phase 1b trial
Bellicum Pharmaceuticals BPX-603 tumors that express human epidermal growth factor 2 first patient enrolled in phase 1/2 trial
Nektar Therapeutics NKTR-255 relapsed or refractory head and neck squamous cell carcinoma or colorectal cancer first patient dosed in phase 1/2 trial
Prevail Therapeutics PR006 frontotemporal dementia patients with GRN mutations first patient dosed in phase 1/2 trial
Hepion Pharmaceuticals CRV431 nonalcoholic steatohepatitis first patient dosed in second dosing cohort of phase 2a trial
PureTech Health LYT-100 (deupirfenidone) breast cancer-related, upper limb secondary lymphedema initiation of phase 2a trial
Bellus Health BLU-5937 chronic pruritus associated with atopic dermatitis first patient dosed in phase 2 trial
Daiichi Sankyo datopotamab deruxtecan (DS-1062) patients with advanced or metastatic nonsmall-cell lung cancer with actionable genomic alterations with progression on or after at least one tyrosine kinase inhibitor and at least one regimen of platinum-based chemotherapy initiation of phase 2 trial
DiaMedica Therapeutics DM199 chronic kidney disease last patient enrolled in phase 2 trial
Elysium Health BASIS prevention of acute kidney injury in patients that have undergone a cardiac surgery initiation of phase 2 trial
Emalex Biosciences ecopipam stuttering first adult patient dosed in phase 2 trial
Harmony Biosciences pitolisant excessive daytime sleepiness and other key symptoms in patients with Prader-Willi Syndrome first patient enrolled in phase 2 trial
Innovent BI310 in combination with TYVY patients with second-line or above advanced cervical cancer first patient dosed in phase 2 trial
REGENXBIO suprachoroidal delivery of RGX-314 using the SCS Microinjector diabetic retinopathy first patient dosed in phase 2 trial
Sanofi fitusiran hemophilia A or B patient dosing resumed in phase 2 trial
Verastem Oncology VS-6766 KRAS mutant nonsmall-cell lung cancer initiation of phase 2 trial
Kiniska vixarelimab prurigo nodularis patient dosing initiated in phase 2b trial
Daiichi Sankyo datopotamab deruxtecan (DS-1062) patients with advanced or metastatic nonsmall-cell lung cancer without actionable genomic alterations who have previously received platinum-based chemotherapy and immunotherapy initiation of phase 3 trial
Erytech Pharma eryaspase second-line metastatic pancreatic cancer patient enrollment complete in phase 3 trial
Amgen sotorasib patients locally advanced or metastatic nonsmall-cell lung cancer with KRAS G12C mutation Breakthrough Therapy designation granted by the FDA
Avelas Biosciences pegloprastide (AVB-620) intraoperative detection and visualization of positive margins during breast cancer surgery Breakthrough Therapy designation granted by the FDA
Cyprium Therapeutics CUTX-101 Menkes disease Breakthrough Therapy designation granted by the FDA
IO Biotech IO102 and IO103 with anti-PD-1 mAb unresectable/ metastatic melanoma Breakthrough Therapy designation granted by the FDA
Novartis iptacopan (LNP023) paroxysmal nocturnal hemoglobinuria Breakthrough Therapy designation granted by the FDA
Novartis iptacopan (LNP023) C3 glomerulopathy Rare Pediatric Disease designation granted by the FDA
GlaxoSmithKlien Benlysta lupus nephritis approved by the FDA
MacroGenics Margenza (margetuximab-cmkb) adults with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease approved by the FDA

 

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing